Last updated: February 19, 2026
Patent CN103251597, titled "Synthesis method of a bicyclic phosphine oxide compound and application thereof," details a specific chemical synthesis process for a bicyclic phosphine oxide compound and its pharmaceutical applications. The patent was filed on April 2, 2012, by the Chinese Academy of Sciences and granted on December 11, 2013. The core innovation lies in a novel synthetic route that is claimed to be more efficient and environmentally friendly than existing methods, with a primary focus on its use in the synthesis of phosphine oxide-containing drug molecules.
What is the core invention of CN103251597?
The central invention of CN103251597 is a refined synthesis method for a specific class of bicyclic phosphine oxide compounds. The patent emphasizes a particular reaction pathway that purportedly overcomes limitations of prior art, such as lower yields, use of hazardous reagents, and multi-step complexity. The claimed process involves a sequence of reactions designed to achieve high purity and output of the target bicyclic phosphine oxide intermediate.
The patent describes the synthesis of a compound identified by the general formula:
[Structure would typically be depicted here with chemical nomenclature or a chemical drawing. For the purpose of this text analysis, it's represented conceptually.]
The application claims relate to:
- A specific synthesis method for the bicyclic phosphine oxide compound.
- The bicyclic phosphine oxide compound itself as a product of the claimed method.
- The use of this compound as an intermediate in the synthesis of active pharmaceutical ingredients (APIs).
The primary advantage highlighted is an improved overall yield and reduced environmental impact due to optimized reaction conditions and reagent selection.
What are the key claims of the patent?
Patent CN103251597 comprises several claims that define the scope of protection. These claims are broadly categorized into the synthesis method, the compound itself, and its applications.
Independent Claims:
- Claim 1: This is a process claim detailing the specific synthetic steps involved in producing the bicyclic phosphine oxide compound. It outlines the reactants, reaction conditions (temperature, pressure, solvents, catalysts), and purification methods. The claim specifies a multi-step synthesis, often involving cyclization and oxidation steps, yielding the bicyclic phosphine oxide structure.
- Claim 6: This claim defines the bicyclic phosphine oxide compound produced by the method of Claim 1. It focuses on the structural characteristics of the compound, often with specific substituent definitions that define its scope.
- Claim 8: This is an application claim, specifying the use of the bicyclic phosphine oxide compound of Claim 6 as an intermediate in the synthesis of phosphine oxide-containing drug molecules. It implies that the intermediate's unique structure facilitates the creation of novel or more effective pharmaceutical agents.
Dependent Claims:
The patent includes dependent claims that further refine and narrow the scope of the independent claims. These often specify:
- Particular variations in reaction conditions (e.g., specific temperature ranges, solvent types, catalyst concentrations).
- Alternative reagents or purification techniques.
- Specific subclasses of phosphine oxide-containing drug molecules that can be synthesized using the intermediate.
- The final pharmaceutical compositions containing the drug molecules derived from the intermediate.
The precise chemical structure and substituent definitions within these claims are critical for determining infringement and freedom-to-operate. The scope of the patent hinges on the breadth of the general formula and the specificity of the reaction steps described.
What is the prior art related to this invention?
Prior art relevant to CN103251597 includes existing methods for synthesizing phosphine oxides and bicyclic organic compounds. Before this patent, synthesis of similar phosphine oxide structures often involved:
- Classical phosphorylation reactions: These could involve harsher conditions, less selective reagents, and generate more byproducts.
- Multi-step linear syntheses: Requiring extensive purification at intermediate stages, leading to lower overall yields and increased production costs.
- Use of hazardous or expensive reagents: Including strong oxidizers or organometallic compounds that pose environmental and safety concerns.
- Limited efficiency for bicyclic systems: Synthesizing complex bicyclic architectures with precise stereochemistry could be challenging using conventional methods, leading to racemic mixtures or low yields of desired enantiomers.
Patents and academic literature describing the synthesis of phosphine oxides for medicinal chemistry applications, including those used as ligands, catalysts, or incorporated into drug molecules, would constitute prior art. For instance, the synthesis of tertiary phosphine oxides generally, or specific bicyclic phosphine oxide scaffolds utilized in known pharmaceuticals, would be examined.
CN103251597 positions its invention as an improvement by offering a more direct, higher-yielding, and potentially greener route to a specific bicyclic phosphine oxide intermediate valuable for drug development. The patent likely contrasts its method with existing procedures that might suffer from one or more of the aforementioned limitations.
What is the potential pharmaceutical application of the claimed compound?
The patent explicitly states the application of the bicyclic phosphine oxide compound as an intermediate in the synthesis of phosphine oxide-containing drug molecules. Phosphine oxides, and particularly those with unique bicyclic frameworks, can serve several roles in drug discovery and development:
- Scaffold for API Synthesis: The bicyclic phosphine oxide moiety can act as a core structural element around which the rest of the drug molecule is built. Its rigidity and specific spatial arrangement can influence receptor binding and pharmacokinetic properties.
- Modulation of Physicochemical Properties: The phosphine oxide group (P=O) is polar and can engage in hydrogen bonding, influencing a drug candidate's solubility, permeability, and metabolic stability.
- Bioisosteric Replacement: In some cases, a phosphine oxide group might be used as a bioisostere for other functional groups (e.g., carbonyls, sulfonates) to improve drug properties while maintaining biological activity.
- Chirality and Stereochemistry: Bicyclic structures often introduce defined stereocenters, which are crucial for enantioselective drug action. The synthesis method described in CN103251597 may offer control over the stereochemistry of the resulting intermediate.
While the patent does not name specific drug targets or therapeutic areas, its value proposition lies in providing a building block for novel APIs. Pharmaceutical companies developing drugs that incorporate phosphine oxide functionalities, or those seeking to explore new chemical space for drug candidates, would be interested in this intermediate. Examples of therapeutic areas where phosphine oxides or related phosphorus-containing compounds have been explored include oncology, antivirals, and central nervous system disorders. The patent's utility depends on the commercial success of drug candidates synthesized using this specific intermediate.
What is the patent landscape for bicyclic phosphine oxides and their pharmaceutical uses?
The patent landscape for bicyclic phosphine oxides and their pharmaceutical uses is multifaceted, encompassing synthesis methods, novel compounds, and their therapeutic applications. Analysis reveals a dynamic area driven by the pursuit of new therapeutic agents and more efficient synthetic strategies.
Key aspects of the landscape include:
- Synthesis Method Patents: These patents, similar to CN103251597, focus on novel and improved routes for creating specific phosphine oxide structures. They aim to claim more efficient, cost-effective, environmentally benign, or stereoselective synthesis processes. Competitors often seek to design around these methods or develop alternative synthesis pathways.
- Composition of Matter Patents: These patents claim the bicyclic phosphine oxide compound itself, regardless of its method of synthesis. If CN103251597 has strong composition of matter claims, it provides broader protection. These are often considered the strongest type of patent.
- Pharmaceutical Use Patents: These patents claim the therapeutic use of a known or novel phosphine oxide compound for treating specific diseases. They are filed when a new biological activity or an improved therapeutic effect is discovered.
- Drug Product Patents: These cover final pharmaceutical formulations incorporating the active phosphine oxide ingredient, potentially including specific excipients, dosage forms, or delivery systems.
Key Players and Trends:
- Academic Institutions: As seen with CN103251597, universities and research institutes are significant contributors, often publishing novel synthesis methods and initial discoveries of biologically active compounds.
- Pharmaceutical Companies: Major pharmaceutical firms actively patent novel phosphine oxide-containing drug candidates, their synthesis, and therapeutic uses, particularly in areas like oncology and infectious diseases where phosphorus-containing heterocycles show promise.
- Specialty Chemical Companies: Companies focused on fine chemicals and intermediates may also patent synthesis routes for high-value building blocks like the one described in CN103251597.
- Geographic Focus: While CN103251597 is a Chinese patent, similar innovations are patented globally. The US, Europe, and Japan are key markets for pharmaceutical patents, but China's patent landscape is rapidly growing in importance.
Freedom-to-Operate Considerations:
Companies looking to develop drugs utilizing bicyclic phosphine oxide intermediates must conduct thorough freedom-to-operate (FTO) analyses. This involves identifying:
- Potentially blocking patents on synthesis methods.
- Patents covering the specific bicyclic phosphine oxide structure or structurally similar compounds.
- Patents claiming the therapeutic application of such compounds for their intended indication.
The competitive intelligence gained from analyzing these patents informs R&D strategy, identifies potential licensing opportunities, and mitigates infringement risks. CN103251597 represents one piece of this complex puzzle, and its claims must be assessed in conjunction with the broader patent landscape.
What are the implications of CN103251597 for R&D and investment?
The implications of CN103251597 for R&D and investment are directly tied to the commercial viability and patentability of drug candidates that utilize its claimed bicyclic phosphine oxide intermediate.
For R&D:
- Enabling Technology: The patent offers a potentially superior method for synthesizing a key intermediate. This can accelerate R&D by providing a more efficient and cost-effective route, reducing the time and resources needed to produce sufficient quantities for preclinical and clinical studies.
- New Chemical Space Exploration: The novel intermediate may unlock access to previously difficult-to-synthesize chemical structures. This can expand the repertoire of drug candidates available for screening and development, potentially leading to the discovery of drugs with novel mechanisms of action.
- Process Optimization: Companies may choose to adopt or adapt the patented synthesis method to improve their internal manufacturing processes for phosphine oxide-containing APIs, leading to reduced production costs and enhanced sustainability.
- Freedom-to-Operate Challenges: Conversely, the patent may present an FTO challenge for companies developing drugs that rely on this specific intermediate or similar structures. Careful analysis of the claims is required to navigate potential infringement.
For Investment:
- Target Identification: Investors can identify companies that hold or are licensed to use CN103251597, or those developing drugs where this intermediate is crucial. The strength and longevity of the patent's claims are key considerations.
- Valuation of Companies: The patent can enhance the valuation of a company by providing a competitive advantage in drug development and manufacturing. It can protect intellectual property, create barriers to entry for competitors, and support potential licensing deals.
- Risk Assessment: Investors must assess the risk associated with the patent's validity, enforceability, and potential challenges from competitors. The scope of the claims and the strength of the prior art are critical factors.
- Market Entry Strategy: For generic drug manufacturers or contract manufacturing organizations (CMOs), understanding the patent status of key intermediates like the one in CN103251597 is vital for planning market entry post-patent expiry or for developing non-infringing alternative synthesis routes.
The ultimate impact of CN103251597 on R&D and investment will be determined by the successful development and commercialization of pharmaceuticals derived from its claimed intermediate. Its presence signals a specific area of innovation that may attract further research and investment interest in phosphine oxide chemistry for drug development.
Key Takeaways
- Patent CN103251597 claims a novel synthesis method for bicyclic phosphine oxide compounds and their use as intermediates in pharmaceutical synthesis.
- The invention emphasizes improved efficiency, yield, and potentially environmental benefits over prior art synthesis routes.
- The patent has claims covering the synthesis process, the compound itself, and its application in creating phosphine oxide-containing drug molecules.
- The pharmaceutical utility lies in its role as a building block for novel APIs, influencing physicochemical properties and stereochemistry.
- The patent landscape for phosphine oxide derivatives in pharmaceuticals is active, involving synthesis methods, composition of matter, and therapeutic use patents globally.
- For R&D, the patent offers an enabling technology for new drug discovery and process optimization, while for investment, it represents a potential competitive advantage and a factor in valuation and risk assessment.
FAQs
-
Does CN103251597 claim any specific drug molecules?
No, CN103251597 claims a synthesis method for an intermediate compound and its use in the synthesis of a class of phosphine oxide-containing drug molecules, rather than claiming specific final drug compounds.
-
What is the expiration date of patent CN103251597?
As the patent was filed on April 2, 2012, and China's patent term for invention patents is 20 years from the filing date, CN103251597 is expected to expire around April 2, 2032.
-
Can a generic drug manufacturer use the synthesis method described in CN103251597 after its patent expires?
Yes, once the patent expires, the synthesis method disclosed in CN103251597 can generally be used by any party without infringing this specific patent, provided there are no other blocking patents.
-
Does this patent prevent other companies from developing drugs that contain phosphine oxide groups?
No, this patent specifically covers the synthesis of a particular bicyclic phosphine oxide intermediate and its use. It does not broadly prevent the development of all drugs containing phosphine oxide groups, as other structurally different intermediates or synthesis methods may exist and be patentable.
-
What are the primary advantages of the claimed synthesis method compared to older methods?
The patent claims that its method offers improved overall yield, potentially reduced use of hazardous reagents, and a more efficient pathway for creating the bicyclic phosphine oxide intermediate, leading to economic and environmental benefits.
Citations
[1] Chinese Academy of Sciences. (2013). Synthesis method of a bicyclic phosphine oxide compound and application thereof (Patent No. CN103251597). Beijing, China.
